All stakeholders-including pathologists, oncologists, hospital or laboratory managers, and patient advocacy group representatives-are encouraged to evaluate and submit feedback on the draft recommendations of the evidence-based clinical practice guideline "PD-L1 Testing of Patients With Lung Cancer for Immunooncology Therapies."
The draft summary of the guideline's six recommendations is available for public review and comment until April 23, 2021.
Given the rapid evolution of immunotherapy and immunomodulatory drugs, an expert panel has reviewed evidence to develop universally accepted, standardized criteria for immunohistochemistry-based testing of immune checkpoint markers, particularly for PD-L1. The draft recommendations aim to optimize PD-L1 testing for patients with non-small cell lung cancer who are being considered for immunooncology therapy.
Thank you for your consideration.